               SEQUENCE LISTING



<110> AVA Lifescience GmbH



<120> Verfahren zum Nachweis der Veranlagung zur Ausbildung von Blutkrebs



<130> Whatever



<160> 5



<170> BiSSAP 1.3.6



<210> 1

<211> 96

<212> PRT

<213> Homo sapiens





<220> 

<223> IGLV3-21 Allel 01



<400> 1

Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys 

1               5                   10                  15      

Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 

            20                  25                  30          

His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 

        35                  40                  45              

Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 

    50                  55                  60                  

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 

65                  70                  75                  80  

Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His 

                85                  90                  95      







<210> 2

<211> 29

<212> DNA

<213> Homo sapiens





<400> 2

tgtgctggtc atctattatg atagcgacc                                      29





<210> 3

<211> 29

<212> DNA

<213> Homo sapiens





<400> 3

tgtgctggtc gtctatgatg atagcgacc                                      29





<210> 4

<211> 18

<212> DNA

<213> Homo sapiens





<400> 4

agacggccag gattacct                                                  18





<210> 5

<211> 20

<212> DNA

<213> Homo sapiens





<400> 5

agagttggag ccagagaatc                                                20





